Theophilus Owan, MD
Interventional Cardiology · Salt Lake City, UTNPI 1982682647
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Medtronic at 47.0% of the total. Reporting peaked in 2024 at $4,481 and has fallen 98.3% since, to $75 in 2025.
Across 110 payments — averaging $79.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$4K
- Abiomed$221
- Kiniksa Pharmaceuticals, Ltd.$120
- Siemens Medical Solutions USA, Inc.$54
- Edwards Lifesciences$34
- plus $128 from 5 others
What the payments were for
- Travel & lodging$4,74754%
- Food & beverage$4,04446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 62 | $4,130 |
| Abbott | 33 | $4,105 |
| Abiomed | 5 | $221 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $120 |
| Siemens Medical Solutions USA, Inc. | 2 | $54 |
| Edwards Lifesciences | 1 | $34 |
| Novartis | 2 | $33 |
| Biosense Webster, Inc. | 1 | $27 |
| Amgen | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$2,881
- ONYX FRONTIER$1,696
- CoreValve Evolut$1,224
- Diamondback Coronary$151
- DRAGONFLY OPSTAR$149
- Dragonfly OCT$142
- ARCALYST$120
How this compares
$8,791 in reported general payments places this provider in the 60th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $172,948 |
| XareltoRivaroxaban | 38 | $36,592 |
| Repatha SureclickEvolocumab | 14 | $9,707 |
| Metoprolol Succinate | 339 | $6,024 |
| Rosuvastatin Calcium | 380 | $5,985 |
| Losartan Potassium | 373 | $4,929 |
| Atorvastatin Calcium | 386 | $4,406 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 241 | $3,584 |
| ClopidogrelClopidogrel Bisulfate | 251 | $3,107 |
| Ezetimibe | 124 | $3,007 |
| Nitroglycerin | 106 | $2,306 |
| Carvedilol | 214 | $2,278 |
| Eplerenone | 21 | $2,207 |
| Isosorbide Mononitrate | 89 | $2,176 |
| Amiodarone Hcl | 96 | $2,123 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Salt Lake City
- Vamsee YagantiSalt Lake City$390K
- Anwar TandarSalt Lake City$131K
- Stavros DrakosSalt Lake City$79K
- Frederick WeltSalt Lake City$26K
- Scott HackingSalt Lake City$22K
- Eric LindleySalt Lake City$18K
- Lee LinstrothSalt Lake City$14K
- Diana MeloSalt Lake City$4K
- Tara JonesSalt Lake City$4K
- Scott BrewsterSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.